Sam Chun Dang Pharm. Co., Ltd
Financials
Valuation Metrics
Sam Chun Dang Pharm. Co., Ltd's Market Cap is ₩4.5T. At end of 2025 it was ₩5.5T. Ranked #108 of 2,414 in KR market (top 4%), #11 of 1,633 on KOSDAQ (top 0.7%), #8 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.53T KRW | KR#108/2,414 Sec#8/231 |
| Revenue | 259.90B KRW | KR#898/2,414 Sec#44/231 |
| Net Income | 25.47B KRW | KR#615/2,414 Sec#37/231 |
| Total Assets | 575.39B KRW | KR#706/2,414 Sec#38/231 |
| Net Assets | 400.79B KRW | KR#594/2,414 Sec#37/231 |
| Employees | 417 | KR#585/2,414 Sec#49/231 |
| Value | ||
| P/E | 177.81x | KR#1,523/2,414 Sec#104/231 |
| P/B | 11.30x | KR#2,373/2,414 Sec#215/231 |
| P/S | 17.43x | KR#2,327/2,414 Sec#183/231 |
| EV/EBITDA | 255.87x | KR#1,539/2,414 Sec#106/231 |
| FCF Yield | -0.80% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | 6.36% | KR#944/2,414 Sec#65/231 |
| ROA | 4.43% | KR#803/2,414 Sec#63/231 |
| Op. Margin | 6.83% | KR#742/2,414 Sec#61/231 |
| Revenue Growth | 20.83% | KR#533/2,414 Sec#50/231 |
| Financial Health | ||
| Debt Ratio | 43.57% | KR#862/2,414 Sec#100/231 |
| Total Debt | 74.15B KRW | KR#838/2,414 Sec#56/231 |
| FCF | -36.35B KRW | KR#2,019/2,414 Sec#197/231 |
| Cash | 63.02B KRW | KR#652/2,414 Sec#35/231 |
| Current Ratio | 2.21x | KR#791/2,414 Sec#93/231 |
| Net Debt/EBITDA | 0.63x | KR#695/2,414 Sec#43/231 |
| Dividend | ||
| Div. Yield | 0.03% | KR#1,381/2,414 Sec#87/231 |
| Div. Growth | -75.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -3.16% | KR#695/2,414 Sec#40/231 |
| 1M Return | 22.37% | KR#91/2,414 Sec#11/231 |
| From 52W High | -84.34% | KR#2,365/2,414 Sec#222/231 |
| 1Y MDD | -89.32% | KR#2,394/2,414 Sec#229/231 |
| Trading | ||
| Volume | 133,866 shares | KR#781/2,414 Sec#78/231 |
| Trading Value | 25.82B KRW | KR#139/2,414 Sec#9/231 |
| Foreign Own. | 4.77% | KR#896/2,414 Sec#80/231 |
| Per Share | ||
| EPS | 1,086 KRW | KR#693/2,414 Sec#46/231 |
| BPS | 17,086 KRW | KR#621/2,414 Sec#41/231 |
Company Info
Samchundang Pharm, established in 1943 and headquartered in Hwaseong-si, Gyeonggi-do, began as a pharmaceutical manufacturer and seller. By acquiring Optus Pharm in 2013, it became a leading specialized ophthalmic treatment company, producing prescription-based pharmaceuticals including antibiotics, circulatory disease treatments, digestive disease treatments, and eye drops. The company is actively expanding its global market presence by exporting finished pharmaceuticals to Vietnam, Hong Kong, and Singapore.